A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1-7 (TXA-127) for the treatment of severe COVID-19

Crit Care. 2022 Jul 28;26(1):229. doi: 10.1186/s13054-022-04096-9.
No abstract available

Publication types

  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Angiotensin I
  • Antifibrinolytic Agents*
  • Blood Loss, Surgical
  • COVID-19*
  • Double-Blind Method
  • Humans
  • Peptide Fragments
  • Pilot Projects
  • Tranexamic Acid*
  • Treatment Outcome

Substances

  • Antifibrinolytic Agents
  • Peptide Fragments
  • Tranexamic Acid
  • Angiotensin I
  • angiotensin I (1-7)

Associated data

  • ClinicalTrials.gov/NCT04401423